---
title: "Cardiac Transplantation"
order: 5
category: "Cardiac Surgery"
---

# Cardiac Transplantation

## Overview

Cardiac transplantation is the definitive treatment for end-stage heart failure refractory to medical and device therapy. Since the first successful human heart transplant by Dr. Christiaan Barnard in 1967, advances in immunosuppression, organ preservation, rejection surveillance, and postoperative care have dramatically improved outcomes. One-year survival now exceeds 90%, with median survival >12 years. Understanding patient selection, donor management, surgical technique, immunosuppression protocols, and rejection monitoring is essential for successful transplantation.

## Indications and Patient Selection

### Indications for Heart Transplantation

**Class I Recommendations**
- **Advanced heart failure** (NYHA Class III-IV) despite optimal medical therapy
- **Refractory cardiogenic shock** requiring mechanical circulatory support
- **Severe symptoms** with:
  - Peak VO2 <12 mL/kg/min (or <50% predicted) on cardiopulmonary exercise testing
  - Refractory angina not amenable to revascularization
  - Recurrent life-threatening ventricular arrhythmias despite ICD, ablation, medical therapy

**Common Etiologies of Heart Failure**
- **Ischemic cardiomyopathy** (40-50%): Post-MI, coronary artery disease
- **Non-ischemic dilated cardiomyopathy** (40-50%): Idiopathic, viral myocarditis, alcohol, chemotherapy
- **Valvular heart disease**: Severe unrepairable valve disease
- **Congenital heart disease**: Failed palliation, single ventricle
- **Restrictive cardiomyopathy**: Amyloidosis, sarcoidosis, hemochromatosis
- **Hypertrophic cardiomyopathy**: Refractory symptoms
- **Retransplantation**: Graft failure (chronic rejection, allograft vasculopathy)

### Contraindications

**Absolute Contraindications**
- **Active infection**: Sepsis, active endocarditis (must be treated and cleared)
- **Active malignancy**: Exceptions: Low-risk skin cancers, successful treatment with >5 years cancer-free
- **Severe irreversible pulmonary hypertension**: PVR >5 Wood units, transpulmonary gradient >15-20 mmHg despite vasodilators (risk of RV failure post-transplant)
- **Severe systemic disease**: Advanced liver/kidney failure (consider multi-organ transplant), severe COPD (FEV1 <1 L), severe peripheral vascular disease
- **Substance abuse**: Active tobacco, alcohol, illicit drugs (require documented abstinence ≥6 months)
- **Psychosocial issues**: Non-compliance, inadequate social support, untreated psychiatric illness
- **Advanced age**: >70-75 years (relative, depends on center)

**Relative Contraindications**
- **Obesity**: BMI >35 kg/m² (increases surgical risk, worse outcomes)
- **Diabetes with end-organ damage**: Severe retinopathy, neuropathy, nephropathy
- **Recent pulmonary embolism**: Risk of recurrence
- **Chronic kidney disease**: eGFR <30 mL/min (may require heart-kidney transplant)
- **Frailty, cachexia**: Poor functional status
- **HLA sensitization**: High panel reactive antibodies (PRA) >50% (longer wait, increased rejection risk)

### Pulmonary Hypertension Assessment

**Critical Evaluation**
- **Pulmonary artery systolic pressure (PASP)**: <50 mmHg (normal)
- **Pulmonary vascular resistance (PVR)**: <3 Wood units (normal)
- **Transpulmonary gradient (TPG)**: Mean PAP - PCWP <12 mmHg (normal)

**Reversibility Testing**
- If PVR >3 Wood units, perform vasodilator challenge (nitroprusside, nitric oxide, milrinone)
- **Reversible pulmonary hypertension**: PVR reduces to <3 Wood units or <2.5 with vasodilators → transplant acceptable
- **Fixed pulmonary hypertension**: PVR remains >5 Wood units → contraindication (high risk of RV failure)

## Donor Selection and Allocation

### Donor Criteria

**Ideal Donor**
- **Age**: <55 years (older donors acceptable for older recipients)
- **ABO compatibility**: Required (ABO-incompatible transplants only in infants <1 year)
- **Size matching**: Donor weight 70-130% of recipient weight
- **Normal cardiac function**: Echocardiography showing EF >50%, no significant valvular disease, no wall motion abnormalities
- **Minimal inotropic support**: Low-dose vasopressors acceptable
- **Short ischemic time**: Ideally <4 hours (prolonged ischemia increases primary graft dysfunction risk)

**Donor Evaluation**
- **Cause of death**: Traumatic brain injury, intracranial hemorrhage, anoxic brain injury
- **Echocardiography**: Assess structure and function
- **Coronary angiography**: Males >45 years, females >50 years, or risk factors (rule out CAD)
- **Serologies**: HIV, hepatitis B/C, CMV, EBV, toxoplasmosis
- **Troponin**: Mild elevation acceptable if echocardiography normal (stress-induced cardiomyopathy from brain death)

**Marginal Donors (Extended Criteria Donors)**
- Age >55 years
- LV hypertrophy, mild LV dysfunction (EF 40-50%)
- Cocaine use, heavy smoking
- Prolonged ischemic time (4-6 hours)
- Used selectively for older, sicker recipients (higher UNOS status)

### Organ Allocation System (UNOS)

**Status Tiers** (U.S. System, 2018 Update)
- **Status 1**: Highest priority
  - ECMO, total artificial heart, IABP, ventilator
  - High-dose or multiple inotropes
- **Status 2**:
  - LVAD with complications (arrhythmias, device malfunction)
  - Stable inotropes
- **Status 3**: LVAD, stable
- **Status 4**: All other candidates
- **Status 7**: Temporarily inactive (too sick or too well)

**Allocation Factors**
- Status tier
- Time on waiting list
- Geographic proximity (local → regional → national)
- Size and ABO compatibility

**Waitlist Mortality**
- Overall: ~10-15% mortality while waiting
- Higher for Status 1 patients

### Donor-Recipient Matching

**Size Matching**
- **Donor:Recipient weight ratio**: 0.7-1.3 (ideally ~1.0)
- **Undersized donor** (<0.7): Risk of donor heart failure (inadequate cardiac output)
- **Oversized donor** (>1.3): Technical difficulty (large heart in small chest)

**ABO Matching**
- Identical or compatible required (O universal donor, AB universal recipient)

**HLA Matching**
- Not routinely performed for heart transplant (unlike kidney)
- **HLA sensitization** (high PRA): Prolongs wait time, increases rejection risk
  - **PRA >50%**: Virtual crossmatch to avoid incompatible donors
  - **Desensitization**: Plasmapheresis, IVIG, rituximab

**CMV Matching**
- Prefer CMV-negative donor for CMV-negative recipient (reduces CMV disease risk)
- If CMV mismatch (D+/R-), prophylaxis required

## Surgical Technique

### Donor Cardiectomy

**Procedure**
1. **Median sternotomy**
2. **Cardiac assessment**: Direct visualization, palpation of coronary arteries
3. **Cardioplegia administration**: Antegrade cold cardioplegia via aortic root
4. **Topical cooling**: Iced saline
5. **Cardiectomy**:
   - Divide IVC, SVC
   - Divide pulmonary veins (leave LA cuff)
   - Divide aorta and pulmonary artery
6. **Preservation**: Place heart in cold preservation solution (University of Wisconsin, Celsior, Custodiol), triple-bag, ice
7. **Transport**: Rapid transport to recipient hospital (minimize ischemic time)

### Recipient Cardiectomy and Transplantation

**Anesthesia and Preparation**
- General anesthesia, intubation
- Arterial line, central venous access, PA catheter
- TEE monitoring
- Prepare for CPB

**Operative Technique**

**Standard Biatrial Technique (Lower-Shumway)**
- Historical technique, less commonly used

**Bicaval Technique (Preferred)**

1. **Median sternotomy**
2. **Cardiopulmonary bypass**:
   - Aortic cannulation
   - Bicaval cannulation (SVC and IVC)
3. **Recipient cardiectomy**:
   - Cross-clamp aorta
   - Divide aorta and pulmonary artery
   - Remove native ventricles
   - **Preserve**: Recipient atria (biatrial) or recipient SVC/IVC cuffs and pulmonary vein cuffs (bicaval)
4. **Donor heart preparation**:
   - Open left atrium (from pulmonary veins)
   - Inspect mitral valve, septum
   - Remove air from left ventricle
5. **Implantation** (Bicaval Technique):
   - **Left atrial anastomosis**: Donor LA to recipient LA cuff (around pulmonary veins)
   - **IVC anastomosis**: Donor IVC to recipient IVC
   - **SVC anastomosis**: Donor SVC to recipient SVC
   - **Pulmonary artery anastomosis**: Donor PA to recipient PA
   - **Aortic anastomosis**: Donor aorta to recipient aorta
6. **De-airing**: Evacuate air from left heart chambers
7. **Remove aortic cross-clamp**: Reperfusion of donor heart
8. **Wean cardiopulmonary bypass**:
   - Allow heart to recover, begin beating
   - Temporary pacing if needed (atrial, AV sequential)
   - Inotropic support (dobutamine, milrinone, epinephrine)
9. **Hemostasis and closure**

**Bicaval vs. Biatrial Technique**
- **Bicaval advantages**:
  - Preserves atrial geometry
  - Lower risk of atrial arrhythmias, tricuspid regurgitation, SVC syndrome
  - Improved hemodynamics
- **Bicaval preferred** in modern practice

### Ischemic Time

- **Cold ischemic time**: Time from donor cardiectomy to recipient reperfusion
- **Goal**: <4 hours (optimal <3 hours)
- **Prolonged ischemic time** (>4-6 hours): Increased primary graft dysfunction, mortality

## Postoperative Management

### Immediate Postoperative (ICU)

**Hemodynamic Management**

**Primary Graft Dysfunction (PGD)**
- **Definition**: Donor heart failure requiring high-dose inotropes, IABP, ECMO in first 24 hours
- **Incidence**: 5-10%
- **Causes**: Prolonged ischemic time, donor-recipient size mismatch, elevated PVR, preservation injury
- **Management**:
  - **Inotropes**: Dobutamine, milrinone, epinephrine, isoproterenol
  - **Mechanical support**: IABP, ECMO, temporary VAD
  - **Pulmonary vasodilators**: Inhaled nitric oxide, sildenafil (if elevated PVR, RV dysfunction)

**RV Failure**
- Common early complication (donor RV faces elevated PVR in recipient)
- Management: Pulmonary vasodilators (inhaled NO, sildenafil), inotropes (milrinone, dobutamine), optimize preload

**Arrhythmias**
- **Bradycardia**: Common (denervated heart, slower intrinsic rate)
  - Temporary pacing wires placed at time of surgery
  - Isoproterenol (increase HR)
  - Permanent pacemaker if persistent high-grade AV block (rare)
- **Atrial arrhythmias**: Atrial fibrillation, flutter (especially biatrial technique)
- **Ventricular arrhythmias**: Rare, concerning for rejection or ischemia

**Hemodynamic Monitoring**
- Arterial line, CVP, PA catheter
- TEE: Assess ventricular function, valve function, pericardial effusion

**Immunosuppression Initiation**
- Begin induction immunosuppression intraoperatively or immediately postoperatively

### Intermediate Postoperative

**Ventilation**
- Extubation when hemodynamically stable, awake, adequate oxygenation/ventilation
- Typically 12-24 hours post-op

**Renal Function**
- Monitor: Creatinine, urine output
- **Acute kidney injury**: Common (CPB, inotropes, calcineurin inhibitors)
- Avoid nephrotoxins, optimize hemodynamics

**Infection Prophylaxis**
- **Antibiotics**: Perioperative cephalosporin × 24-48 hours
- **Antiviral**: CMV prophylaxis (valganciclovir) if D+/R- or R+
- **Antifungal**: Fluconazole or nystatin (oral candidiasis prevention)
- **PCP prophylaxis**: Trimethoprim-sulfamethoxazole (or alternative)

**Rejection Surveillance**
- **Endomyocardial biopsy**: Gold standard for rejection diagnosis
  - **First year**: Weekly × 4-6 weeks, then every 2-4 weeks × 3 months, then every 3 months
  - **After first year**: Every 6-12 months or if clinically indicated
- **Non-invasive monitoring**: Gene expression profiling (AlloMap), donor-derived cell-free DNA (investigational)

## Immunosuppression

### Goals

- **Prevent acute rejection**: Suppress T-cell mediated immune response
- **Prevent chronic rejection**: Minimize allograft vasculopathy
- **Minimize toxicity**: Balance immunosuppression with infection risk, malignancy risk, drug side effects

### Induction Immunosuppression

**Purpose**: Intense early immunosuppression to prevent acute rejection in first weeks-months

**Agents**

**IL-2 Receptor Antagonists (Anti-CD25)**
- **Basiliximab** (Simulect): Monoclonal antibody, blocks IL-2 receptor
- Dosing: Day 0 and Day 4 post-transplant
- **Advantages**: Well-tolerated, no increased infection risk
- Most commonly used induction agent

**Lymphocyte-Depleting Agents**
- **Rabbit Antithymocyte Globulin (rATG, Thymoglobulin)**: Polyclonal antibody, depletes T-cells
- Dosing: 1-1.5 mg/kg daily × 3-7 days
- **Indications**: High-risk patients (retransplantation, high PRA, delayed renal function)
- **Adverse effects**: Cytokine release syndrome (fever, rigors), serum sickness, leukopenia, thrombocytopenia, increased infection risk

**Alemtuzumab (Campath)**
- Anti-CD52, depletes lymphocytes
- Less commonly used

### Maintenance Immunosuppression

**Triple-Drug Regimen (Standard)**

**1. Calcineurin Inhibitor (CNI)**

**Tacrolimus (Prograf, FK506)**
- **Mechanism**: Inhibits calcineurin → blocks T-cell activation
- **Dosing**: Oral, twice daily; target trough levels 8-12 ng/mL (early), 6-10 ng/mL (late)
- **Preferred over cyclosporine** (lower rejection rates, better survival)
- **Adverse effects**:
  - **Nephrotoxicity**: Dose-dependent, monitor creatinine
  - **Neurotoxicity**: Tremor, headache, seizures (rare)
  - **Diabetes**: New-onset diabetes after transplant (NODAT) in 20-30%
  - **Hypertension**
  - **Hyperkalemia**

**Cyclosporine (Neoral, Sandimmune)**
- Similar mechanism to tacrolimus
- Less commonly used (higher rejection vs. tacrolimus)
- **Adverse effects**: Nephrotoxicity, hypertension, hirsutism, gingival hyperplasia, hyperlipidemia

**2. Antiproliferative Agent**

**Mycophenolate Mofetil (MMF, CellCept) or Mycophenolic Acid (Myfortic)**
- **Mechanism**: Inhibits inosine monophosphate dehydrogenase → blocks purine synthesis → inhibits lymphocyte proliferation
- **Dosing**: MMF 1000-1500 mg PO BID
- **Adverse effects**:
  - **GI**: Diarrhea, nausea, abdominal pain (dose-limiting)
  - **Bone marrow suppression**: Leukopenia, anemia, thrombocytopenia

**Azathioprine (Imuran)**
- Older antiproliferative agent, less commonly used
- Mechanism: Purine analog, inhibits DNA synthesis

**3. Corticosteroids**

**Prednisone**
- **Mechanism**: Broad anti-inflammatory, suppresses T-cell activation
- **Dosing**: High-dose initially (0.5-1 mg/kg), taper over weeks-months to maintenance dose (5-10 mg daily)
- **Steroid withdrawal**: Some centers discontinue steroids at 6-12 months (reduces side effects)
- **Adverse effects**: Diabetes, hypertension, osteoporosis, weight gain, Cushingoid features, infection risk

### Alternative Agents

**mTOR Inhibitors**

**Sirolimus (Rapamune), Everolimus (Zortress)**
- **Mechanism**: Inhibit mammalian target of rapamycin (mTOR) → block T-cell proliferation
- **Uses**:
  - **CNI minimization/avoidance**: Renal-sparing strategy (mTOR inhibitors less nephrotoxic)
  - **Allograft vasculopathy**: mTOR inhibitors may slow progression (antiproliferative effect on smooth muscle)
- **Adverse effects**:
  - **Wound healing**: Impaired healing, increased wound complications (avoid early post-op)
  - **Bone marrow suppression**: Leukopenia, thrombocytopenia, anemia
  - **Hyperlipidemia**: Increase cholesterol, triglycerides
  - **Proteinuria**
  - **Interstitial pneumonitis** (rare)

## Rejection

### Types of Rejection

**Hyperacute Rejection**
- **Timing**: Minutes to hours post-transplant
- **Mechanism**: Preformed antibodies against donor HLA or ABO antigens
- **Presentation**: Immediate graft failure in OR
- **Prevention**: ABO compatibility, virtual crossmatch for sensitized recipients
- **Treatment**: None effective; requires retransplantation
- **Rare** with modern crossmatching

**Acute Cellular Rejection (ACR)**
- **Timing**: Weeks to months (peak incidence 1-6 months, can occur later)
- **Mechanism**: T-cell mediated immune response against donor myocardium
- **Incidence**: 20-30% in first year

**Antibody-Mediated Rejection (AMR, Humoral Rejection)**
- **Mechanism**: Donor-specific antibodies (DSA) against donor HLA antigens
- **Incidence**: 10-20% in first year
- **Risk factors**: High PRA, HLA sensitization, non-adherence
- **Associated with**: Worse long-term outcomes, allograft vasculopathy

**Chronic Rejection**
- **Cardiac allograft vasculopathy (CAV)**: Proliferative arteriopathy affecting coronary arteries
- Discussed separately below

### Acute Cellular Rejection (ACR)

**Diagnosis**

**Endomyocardial Biopsy**
- **Gold standard**
- Transvenous approach (internal jugular vein → right ventricle)
- 4-6 samples from RV septum
- **ISHLT Grading** (2004 Revision):
  - **Grade 0R**: No rejection
  - **Grade 1R (Mild)**: Interstitial and/or perivascular infiltrate with ≤1 focus of myocyte damage
  - **Grade 2R (Moderate)**: Two or more foci of infiltrate with myocyte damage
  - **Grade 3R (Severe)**: Diffuse infiltrate with multifocal myocyte damage ± edema, hemorrhage, vasculitis

**Clinical Presentation**
- **Asymptomatic**: Most cases detected on surveillance biopsy
- **Symptomatic**: Dyspnea, fatigue, arrhythmias, heart failure, hypotension (severe rejection)

**Treatment**

**Grade 1R (Mild)**
- **Observation**: Usually not treated
- **Increase immunosuppression**: If persistent or recurrent

**Grade 2R (Moderate)**
- **Pulse corticosteroids**: Methylprednisolone 500-1000 mg IV daily × 3 days
- **Increase maintenance immunosuppression**: Optimize tacrolimus levels, increase MMF dose
- **Repeat biopsy**: 1-2 weeks to assess response

**Grade 3R (Severe)**
- **Pulse corticosteroids**: High-dose methylprednisolone
- **Antithymocyte globulin (rATG)**: If steroid-resistant or hemodynamic compromise
- **Increase maintenance immunosuppression**
- **Repeat biopsy**: Weekly until resolution

**Outcomes**
- **Grade 1R**: Benign, excellent outcomes
- **Grade 2R-3R**: Increased risk of allograft vasculopathy, mortality
- **Steroid-resistant rejection**: Poor prognosis, consider retransplantation

### Antibody-Mediated Rejection (AMR)

**Diagnosis**

**Criteria** (ISHLT 2013)
1. **Histopathology**: Capillary injury, endothelial swelling, macrophage infiltration
2. **Immunopathology**: Positive C4d staining (complement deposition in capillaries) or CD68+ macrophages
3. **Donor-specific antibodies (DSA)**: Presence of anti-HLA antibodies
4. **Graft dysfunction**: Evidence of cardiac dysfunction

**Clinical Presentation**
- Dyspnea, heart failure, arrhythmias
- May be asymptomatic (detected on surveillance biopsy)

**Treatment**
- **Plasmapheresis**: Remove circulating antibodies (5-7 sessions)
- **IVIG**: 2 g/kg (modulates immune response, blocks Fc receptors)
- **Rituximab**: Anti-CD20, depletes B-cells (1-2 doses)
- **Bortezomib**: Proteasome inhibitor, depletes plasma cells (investigational)
- **Optimize maintenance immunosuppression**: Increase tacrolimus, MMF

**Outcomes**
- **AMR is more refractory** than ACR
- Increased risk of allograft vasculopathy, graft loss

## Cardiac Allograft Vasculopathy (CAV)

### Pathophysiology

- **Chronic rejection**, leading cause of late graft failure (>1 year post-transplant)
- **Mechanism**: Immune-mediated and non-immune injury → diffuse concentric intimal proliferation in coronary arteries
- **Differs from native CAD**: Diffuse, concentric, involves entire coronary tree (including distal vessels), no focal plaques
- **Incidence**: 30% at 5 years, 50% at 10 years

**Risk Factors**
- **Immunologic**: Acute rejection episodes, AMR, HLA mismatch, DSA
- **Non-immunologic**: Donor age, CMV infection, hyperlipidemia, hypertension, diabetes

### Diagnosis

**Coronary Angiography**
- **Annual screening** starting 1 year post-transplant
- **Underestimates CAV**: Diffuse concentric narrowing appears "normal" (no focal stenoses)
- Severe CAV: Pruning of distal vessels, diffuse narrowing

**Intravascular Ultrasound (IVUS)**
- **Gold standard** for CAV diagnosis
- Detects intimal thickening
- **Maximal intimal thickness (MIT)** >0.5 mm at 1 year is abnormal

**Coronary CT Angiography, Stress Testing**
- Adjuncts, limited sensitivity for CAV

### Clinical Presentation

- **Asymptomatic**: Denervated heart (no angina)
- **Heart failure**: Gradual decline in function
- **Sudden cardiac death, MI**: Acute thrombosis

### Treatment

**Prevention**
- **mTOR inhibitors**: Sirolimus, everolimus (slow CAV progression)
- **Statins**: All transplant recipients (reduce CAV)
- **Aspirin**: Antiplatelet therapy
- **Optimize immunosuppression**: Prevent acute rejection

**Intervention**
- **PCI**: Percutaneous intervention for focal lesions (rare in CAV, which is diffuse)
- **CABG**: Limited role (diffuse distal disease)
- **Retransplantation**: Only definitive treatment for severe CAV

## Complications

### Infection

**Highest Risk Period**: First 6 months post-transplant (intense immunosuppression)

**Bacterial Infections**
- **Pneumonia, UTI, bloodstream infections**: Most common
- **Prophylaxis**: Perioperative antibiotics

**Viral Infections**
- **CMV**: Most significant viral pathogen
  - Incidence: 20-30% in first year
  - **CMV disease**: Fever, leukopenia, GI symptoms, pneumonitis, hepatitis
  - **Prophylaxis**: Valganciclovir (D+/R- or R+) × 3-6 months
  - **Treatment**: IV ganciclovir or oral valganciclovir
- **EBV**: Risk factor for post-transplant lymphoproliferative disorder (PTLD)
- **HSV, VZV**: Reactivation (prophylaxis with acyclovir/valacyclovir)

**Fungal Infections**
- **Aspergillus, Candida**: Increased risk with prolonged immunosuppression
- **Prophylaxis**: Fluconazole (candida), consider antifungal prophylaxis in high-risk patients

**Opportunistic Infections**
- **Pneumocystis jirovecii pneumonia (PCP)**: Prophylaxis with TMP-SMX (lifelong)
- **Toxoplasmosis**: If donor or recipient seropositive (prophylaxis with TMP-SMX or pyrimethamine)

### Malignancy

**Increased Risk**: 2-4× general population (immunosuppression impairs tumor surveillance)

**Skin Cancer**
- **Most common**: Squamous cell carcinoma, basal cell carcinoma
- **Prevention**: Sun protection, annual dermatology screening

**Post-Transplant Lymphoproliferative Disorder (PTLD)**
- **EBV-driven** B-cell lymphoma
- **Incidence**: 1-2% in first year, 5-10% over lifetime
- **Presentation**: Lymphadenopathy, GI mass, CNS lesion
- **Treatment**: Reduce immunosuppression, rituximab, chemotherapy
- **Prognosis**: Variable (50-80% survival)

**Other Malignancies**
- Lung, colon, breast, prostate (age-appropriate screening recommended)

### Renal Dysfunction

**Chronic Kidney Disease (CKD)**
- **Incidence**: 20-30% at 5 years
- **Causes**: Calcineurin inhibitor nephrotoxicity, hypertension, diabetes
- **Management**: CNI minimization (switch to mTOR inhibitor), optimize BP and glucose control

### Allograft Dysfunction

**Primary Graft Dysfunction**: Early (discussed above)

**Late Graft Dysfunction**
- **Acute rejection**: ACR, AMR
- **CAV**: Chronic rejection
- **Medication non-adherence**: Common cause of late rejection, graft loss

### Other Complications

**Hypertension**: 70-90% (calcineurin inhibitors, steroids)

**Diabetes**: 20-30% new-onset (tacrolimus, steroids)

**Hyperlipidemia**: 60-80% (steroids, mTOR inhibitors, cyclosporine)

**Osteoporosis**: Corticosteroids

## Outcomes

### Survival

**1-year survival**: 90-92%

**5-year survival**: 75-80%

**10-year survival**: 55-60%

**Median survival**: ~12-13 years

### Causes of Death

**First 30 Days**
- Primary graft dysfunction (40%)
- Multi-organ failure (20%)
- Infection (15%)

**1 Month - 1 Year**
- Infection (30-40%)
- Acute rejection (10-15%)
- Graft failure (15%)

**>1 Year**
- Cardiac allograft vasculopathy (30-40%)
- Malignancy (20-25%)
- Infection (10-15%)
- Acute rejection (5-10%)

### Quality of Life

- **Excellent functional capacity** in most patients
- Return to work: 50-70%
- NYHA Class I-II: 80-90%
- Exercise capacity: Improved but not normal (denervated heart, chronotropic incompetence)

## Key Points

1. **Heart transplantation** is indicated for end-stage heart failure (NYHA III-IV) refractory to medical therapy with peak VO2 <12 mL/kg/min; 1-year survival exceeds 90%, median survival >12 years.

2. **Severe irreversible pulmonary hypertension** (PVR >5 Wood units despite vasodilators) is an absolute contraindication; increases risk of post-transplant RV failure and mortality.

3. **Bicaval technique** is preferred over biatrial technique for orthotopic heart transplantation; reduces atrial arrhythmias, tricuspid regurgitation, and SVC syndrome.

4. **Cold ischemic time** should be <4 hours (ideally <3 hours); prolonged ischemic time increases primary graft dysfunction risk and mortality.

5. **Triple-drug immunosuppression** (tacrolimus + mycophenolate + prednisone) is the standard maintenance regimen; tacrolimus is preferred over cyclosporine (lower rejection rates).

6. **Acute cellular rejection** (ACR) peaks at 1-6 months; graded by endomyocardial biopsy (Grade 0R-3R); Grade 2R-3R treated with pulse corticosteroids ± antithymocyte globulin.

7. **Antibody-mediated rejection** (AMR) is diagnosed by histopathology (capillary injury), C4d staining, and donor-specific antibodies (DSA); treated with plasmapheresis, IVIG, and rituximab.

8. **Cardiac allograft vasculopathy** (CAV) is chronic rejection affecting 30% at 5 years, 50% at 10 years; diffuse concentric coronary intimal proliferation; only definitive treatment is retransplantation.

9. **CMV infection** complicates 20-30% in the first year, especially in D+/R- mismatch; prophylaxis with valganciclovir × 3-6 months reduces incidence.

10. **Calcineurin inhibitor nephrotoxicity** causes chronic kidney disease in 20-30% at 5 years; CNI minimization with mTOR inhibitors (sirolimus, everolimus) is a renal-sparing strategy.

## References

1. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016;35(1):1-23.

2. Lund LH, Khush KK, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report—2017. J Heart Lung Transplant. 2017;36(10):1037-1046.

3. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-1720.

4. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147-1162.

5. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847-858.

6. Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327-340.

7. Patel JK, Kobashigawa JA. Cardiac transplantation: where are we now? Nat Clin Pract Cardiovasc Med. 2007;4(4):203-210.

8. Hunt SA; International Society for Heart and Lung Transplantation. Taking heart—cardiac transplantation past, present, and future. N Engl J Med. 2006;355(3):231-235.

9. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956.

10. Eurotransplant International Foundation. Annual Report 2018. Leiden, The Netherlands: Eurotransplant International Foundation; 2019.
